Serum Non-coding RNAs for Diagnosis and Stage of Liver Fibrosis

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Aug 22

PMID 35989522

Authors

Chao Liu

Xueyun Hou

Kaixin Mo

Nannan Li

Cheng An

Guijian Liu

Zongdai Pan

Affiliations

Soon will be listed here.

Abstract

Background: All chronic liver diseases could lead to liver fibrosis. Accurate diagnosis and stage of fibrosis were important for the medical determination, management, and therapy. Liver biopsy was considered to be the gold criteria of fibrosis diagnosis. However, liver biopsy was an invasive method with some drawbacks. Non-invasive tests for liver fibrosis included radiologic method and serum-based test. Radiologic examination was influenced by obesity, cost, and availability. Serum-based test was widely used in the screening and diagnostic of liver fibrosis. However, the accuracy was still needed to be improved.

Methods: Recent studies showed serum non-coding RNAs: microRNA, long non-coding RNA(lncRNA), and circular RNA(circRNA), which have the potentiality to be non-invasive markers for liver fibrosis. The recent progress was summarized in this review.

Results: These studies showed serum non-coding RNAs exerted a good diagnostic performance for liver fibrosis. A panel that included several non-coding RNAs could increase the accuracy of single marker.

Conclusions: Serum microRNAs, lncRNAs, and circRNAs could be potential non-invasive markers for diagnosis and stage of liver fibrosis. More high-quality clinical study is needed for further research.

Citing Articles

Identification of serum tsRNA-Thr-5-0015 and combined with AFP and PIVKA-II as novel biomarkers for hepatocellular carcinoma.

Jin K, Wu J, Yang J, Chen B, Xu J, Bao H Sci Rep. 2024; 14(1):28834.

PMID: 39572775 PMC: 11582641. DOI: 10.1038/s41598-024-80592-y.

New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?.

Tagliaferro M, Marino M, Basile V, Pocino K, Rapaccini G, Ciasca G J Pers Med. 2024; 14(8).

PMID: 39201990 PMC: 11355846. DOI: 10.3390/jpm14080798.

Liquid Liver Biopsy for Disease Diagnosis and Prognosis.

Tsoneva D, Ivanov M, Vinciguerra M J Clin Transl Hepatol. 2024; 11(7):1520-1541.

PMID: 38161500 PMC: 10752811. DOI: 10.14218/JCTH.2023.00040.

Serum non-coding RNAs for diagnosis and stage of liver fibrosis.

Liu C, Hou X, Mo K, Li N, An C, Liu G J Clin Lab Anal. 2022; 36(10):e24658.

PMID: 35989522 PMC: 9550980. DOI: 10.1002/jcla.24658.

References

Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C . Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016; 44(8):3865-77. PMC: 4856985. DOI: 10.1093/nar/gkw116. View

Anwar S, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A . Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One. 2012; 7(11):e49462. PMC: 3493531. DOI: 10.1371/journal.pone.0049462. View

Pan Y, Wang J, He L, Zhang F . MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-1/smad Pathway. J Immunol Res. 2021; 2021:6890423. PMC: 8087466. DOI: 10.1155/2021/6890423. View

Deng Z, He Y, Yang X, Shi H, Shi A, Lu L . MicroRNA-29: A Crucial Player in Fibrotic Disease. Mol Diagn Ther. 2017; 21(3):285-294. DOI: 10.1007/s40291-016-0253-9. View

Wang S, Jiang J, Zhang C, Zhang X, Wang C . Serum lincRNA-p21 expression in primary liver diseases and liver metastatic diseases. Pathol Res Pract. 2019; 215(4):779-783. DOI: 10.1016/j.prp.2019.01.014. View

Yu F, Lu Z, Cai J, Huang K, Chen B, Li G . MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis. Cell Cycle. 2015; 14(24):3885-96. PMC: 4825734. DOI: 10.1080/15384101.2015.1120917. View

Lin C, Liao Y, Hsieh P, Lu M, Peng C, Chu P . LncRNA GAS5-AS1 inhibits myofibroblasts activities in oral submucous fibrosis. J Formos Med Assoc. 2017; 117(8):727-733. DOI: 10.1016/j.jfma.2017.09.012. View

Wang K, Li J, Xiong G, He G, Guan X, Yang K . Negative regulation of lncRNA GAS5 by miR-196a inhibits esophageal squamous cell carcinoma growth. Biochem Biophys Res Commun. 2017; 495(1):1151-1157. DOI: 10.1016/j.bbrc.2017.11.119. View

Shi S, Song L, Yu H, Feng S, He J, Liu Y . Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT. Front Pharmacol. 2020; 11:586895. PMC: 7725869. DOI: 10.3389/fphar.2020.586895. View

10.

Xue J, Xiao T, Wei S, Sun J, Zou Z, Shi M . miR-21-regulated M2 polarization of macrophage is involved in arsenicosis-induced hepatic fibrosis through the activation of hepatic stellate cells. J Cell Physiol. 2021; 236(8):6025-6041. DOI: 10.1002/jcp.30288. View

11.

Wei Y, Yan X, Yan L, Hu F, Ma W, Wang Y . Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling. Mol Med Rep. 2017; 16(5):7287-7296. PMC: 5865857. DOI: 10.3892/mmr.2017.7584. View

12.

Huang Y, de Boer W, Adams L, MacQuillan G, Bulsara M, Jeffrey G . Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. J Hepatol. 2014; 61(1):22-7. DOI: 10.1016/j.jhep.2014.02.031. View

13.

Gao Q, Chang X, Yang M, Zheng J, Gong X, Liu H . LncRNA MEG3 restrained pulmonary fibrosis induced by NiO NPs via regulating hedgehog signaling pathway-mediated autophagy. Environ Toxicol. 2021; 37(1):79-91. DOI: 10.1002/tox.23379. View

14.

Omran A, Osman K, Kamel H, Abdel-Naem E, Hasan D . MicroRNA-122 as a Novel Non-Invasive Marker of Liver Fibrosis in Hepatitis C Virus Patients. Clin Lab. 2017; 62(7):1329-1337. DOI: 10.7754/Clin.Lab.2015.151141. View

15.

Wang W, Dong R, Guo Y, He J, Shao C, Yi P . CircMTO1 inhibits liver fibrosis via regulation of miR-17-5p and Smad7. J Cell Mol Med. 2019; 23(8):5486-5496. PMC: 6653252. DOI: 10.1111/jcmm.14432. View

16.

Roderburg C, Urban G, Bettermann K, Vucur M, Zimmermann H, Schmidt S . Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2010; 53(1):209-18. DOI: 10.1002/hep.23922. View

17.

Dong Z, Li S, Wang X, Si L, Ma R, Bao L . lncRNA GAS5 restrains CCl-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway. Am J Physiol Gastrointest Liver Physiol. 2019; 316(4):G539-G550. DOI: 10.1152/ajpgi.00249.2018. View

18.

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

19.

Cao S, Liu W, Li F, Zhao W, Qin C . Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol. 2014; 7(10):6776-83. PMC: 4230116. View

20.

Cai P, Mu Y, Olveda R, Ross A, Olveda D, McManus D . Circulating miRNAs as footprints for liver fibrosis grading in schistosomiasis. EBioMedicine. 2018; 37:334-343. PMC: 6286190. DOI: 10.1016/j.ebiom.2018.10.048. View